Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483264 | 0.72 | PTGDR2 (0.44) | PTGDR2BRD4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL482790 | 0.71 | PTGDR2 (0.39) | PTGDR2BRD4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL482935 | 0.67 | BRD4 (0.33) | BRD4 | |
| SCHEMBL483269 | 0.67 | NR3C2 (0.41) | PTGDR2LMNAMAPT | |
| SCHEMBL16722026 | 0.63 | BRD4 (0.65) | BRD4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL16722028 | 0.63 | BRD4 (0.65) | BRD4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL21261388 | 0.62 | VRK1 (0.51) | BRD4TSHRNPSR1MEN1MAPT | |
| SCHEMBL15880160 | 0.61 | HRH3 (0.47) | — | |
| SCHEMBL30843731 | 0.61 | MAPT (0.48) | BRD4KCNH2MAPTOPRK1 | |
| SCHEMBL15875771 | 0.61 | HRH3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | PTGDR2 120/4885BRD4 1271/4885CACNA1G 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.